Kanghong Pharmaceutical Competitors and Similar CompaniesClear all

Kanghong Pharmaceutical's competitors and similar companies include TCM Biotech, Neofluidics, Lutonix and Intra-Cellular Therapies.

	Kanghong Pharmaceutical Kanghong Pharmaceutical (成都康弘药业集团股份有限公司) is a company that produces and sells biological products.	TCM Biotech TCM Biotech (泰宗生物科技股份有限公司, also known as Taizong Biotechnology) is a biotech company that specializes in the research and development of drugs.	Neofluidics Neofluidics is a company that develops tools and technology for enhanced microfluidics.	Lutonix Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation.	Intra-Cellular Therapies Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS.
Founding Date	Founding Date 1996	Founding Date 1998	Founding Date 2014	Founding Date 2007	Founding Date 2002
Type	Type Public	Type Public	Type Private	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development medical devices	Tags Healthcare biotech drug development medical devices	Tags Healthcare biotech drug development medical devices	Tags Healthcare biotech drug development medical devices	Tags Healthcare biotech drug development medical devices
Locations	Locations Cheng Du Shi, CN HQ	Locations HQ	Locations San Diego, US HQ Lubbock, US	Locations Maple Grove, US HQ	Locations New York, US HQ
Employees	Employees 4,462	Employees N/A	Employees 3	Employees 10	Employees 330352% increase
Valuation ($)	Valuation ($) 2.5 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 8.1 b
Financial
Revenue (est.)	Revenue (est.) ¥4.5b (FY, 2025)	Revenue (est.) NT$666.5m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $680.9m (FY, 2024)
Cost of goods	Cost of goods ¥465.4m (FY, 2025)	Cost of goods NT$315.4m (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥4.1b (FY, 2025)	Gross profit NT$363.6m (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ¥1.1b (FY, 2025)	Net income NT$21m (FY, 2024)	Net income N/A	Net income N/A	Net income ($74.7m) (FY, 2024)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 3.2m	Total funding raised $ 35m	Total funding raised $ 225.3m